Surface Oncology Inc (SURF) gains 1.07%

Surface Oncology Inc (SURF) gains 1.07%

Surface Oncology Inc (NASDAQ: SURF) shares gained 1.07%, or $0.07 per share, to close Friday at $6.59. After opening the day at $6.61, shares of Surface Oncology fluctuated between $6.70 and $6.44. 424,774 shares traded hands a decrease from their 30 day average of 1,051,454. Friday’s activity brought Surface Oncology’s market cap to $286,195,924.

Surface Oncology is headquartered in Cambridge, Massachusetts..

About Surface Oncology Inc

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.

error: Content is protected !!